Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$41.24 USD
+0.08 (0.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $41.30 +0.06 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CLDX 41.24 +0.08(0.19%)
Will CLDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLDX
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Acadia Healthcare (ACHC) Beats Q2 Earnings and Revenue Estimates
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Other News for CLDX
Celldex (CLDX) Receives a Buy from Cantor Fitzgerald
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
Celldex Therapeutics to Present at Upcoming Investor Conferences
Notable Wednesday Option Activity: CLDX, DJT, BOX
Bullish Two Hundred Day Moving Average Cross - CLDX